Skip to main content

Table 3 Performance of the classifier in training and validation studies

From: Validation of a blood protein signature for non-small cell lung cancer

 

Sensitivity (%)

Specificity (%)

Stage I

Stage II-IV

Controls

 

AD

SQ

AD

SQ

Benign nodule

All controls

Data set

      

Training set

33

64

59

84

89

90

95% CI

19-52

35-85

43-74

62-95

82-93

86-93

UHH validation

35

75

51

83

81

81

95% CI

18-57

53-89

36-67

68-93

63-92

63-92

EDRN validation

50

93

79

82

70

71

95% CI

31-69

66-100

52-93

51-96

48-86

59-80

  1. Sensitivity of the classifier in training and validation is calculated by tumor stage and histology. Specificity is calculated for the benign nodule subset and for all controls. 95% CI is the 95% confidence interval.
Back to article page

Clinical Proteomics

ISSN: 1559-0275